挖掘临床数据以发现新型创伤后应激障碍药物
研究利用美国退伍军人事务部电子健康记录数据(N=168,941),构建所有美国食品药品监督管理局批准药物的机制树,用树基扫描统计量识别与创伤后应激障碍症状临床意义改善相关的药物。结果显示,舍曲林等常用药物与症状改善相关但效应较小;部分而非全部直接抗病毒药物与创伤后应激障碍改善呈强关联。
要点
- 在20年随访的168,941例创伤后应激障碍患者中,舍曲林等常用药物与症状改善相关但效应较小。
- 部分用于治疗丙型肝炎病毒的直接抗病毒药物与创伤后应激障碍改善呈强关联。
- 排除同时接受创伤聚焦心理治疗等既定创伤后应激障碍治疗的患者后,上述关联在敏感性分析中依然稳健。
核心结论
- 探索性方法既得出了与创伤后应激障碍药物治疗已知情况一致的发现,也发现了一类可能改善创伤后应激障碍症状的新药物。
研究设计与样本
- 研究利用美国退伍军人事务部的电子健康记录数据,构建所有美国食品药品监督管理局批准药物的机制树,并使用树基扫描统计量进行分析。
- 队列纳入诊断为创伤后应激障碍且在20年期间使用创伤后应激障碍检查表进行重复症状测量的患者(N=168,941)。
主要发现
- 通常用于治疗创伤后应激障碍的药物,如美国食品药品监督管理局批准药物舍曲林,与创伤后应激障碍症状改善相关,但效应较小。
- 用于治疗丙型肝炎病毒的直接抗病毒药物中,部分而非全部与创伤后应激障碍改善呈强关联。
- 排除同时接受创伤聚焦心理治疗等既定创伤后应激障碍治疗的患者后,上述发现在敏感性分析中依然稳健。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite the prevalence and negative impact of posttraumatic stress disorder (PTSD), there are few medications approved by the U.S. Food and Drug Administration for treatment, and approved medications do not work well enough. We leveraged large-scale electronic health record data to identify existing medications that may be repurposed as PTSD treatments. METHODS: We constructed a mechanistic tree of all Food and Drug Administration-approved medications and used the tree-based scan statistic to identify medications associated with greater than expected levels of clinically meaningful improvement in PTSD symptoms using electronic health record data from the U.S. Department of Veterans Affairs. Our cohort included patients with a diagnosis of PTSD who had repeated symptom measurements using the PTSD Checklist over a 20-year period (N = 168,941). We calculated observed numbers based on patients taking each drug or mechanistically related class of drugs and the expected numbers based on the tree as a whole. RESULTS: Medications typically used to treat PTSD, such as the Food and Drug Administration-approved agent sertraline, were associated with improvement in PTSD symptoms, but the effects were small. Several, but not all, direct-acting antivirals used in the treatment of hepatitis C virus demonstrated a strong association with PTSD improvement. The finding was robust to a sensitivity analysis excluding patients who received established PTSD treatments, including trauma-focused psychotherapy, concurrent with hepatitis treatment. CONCLUSIONS: Our exploratory approach both demonstrated findings that are consistent with what is known about pharmacotherapy for PTSD and uncovered a novel class of medications that may improve PTSD symptoms.
引用
- Shiner B, Forehand JA, Rozema L, et al. Mining Clinical Data for Novel Posttraumatic Stress Disorder Medications. Biol Psychiatry. 2021. PMID: 34952698. doi:10.1016/j.biopsych.2021.10.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。